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Background: Mutations of the BCR-ABL1 fusion gene represent a well established cause of resistance to tyrosine
kinase inhibitors. Among the different mutations identified T315I is of particular concern since it is not effectively
targeted by the majority of Tyrosine Kinase Inhibitors so far available. We developed a novel assay based on
peptide nucleic acid (PNA) technology coupled to immunofluorescence microscopy (PNA-FISH) for the specific
detection at a single cell level of BCR-ABL T315I mutation thus improving both, diagnostic resolution and the study of
clonal prevalence. Furthermore we developed an additional method based on PNA directed PCR-clamping for the fast
and easy detection of the mutation.
Results: The PNA directed PCR clamping allows to detect an amount of mutated template as low as 0.5 %. This method
is highly sensitive, specific and cheap and could be applied even in laboratory not equipped for more sophisticated
analysis. Furthermore, the PNA FISH method allows to identify a small amount of progenitor cells still present after
therapy with specific inhibitors.
Conclusions: We present here two different methods based on PNA for the detection of T315I useful for different
purposes. PNA-FISH can be used to study clonal evolution. In addition, this method could help in the study of compound
mutations being able to identify two different mutations in a single cell. PNA directed PCR clamping although not
superior to sequencing can be applied worldwide even in laboratory not equipped to search for mutations.
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Chronic myeloid leukemia (CML) is characterized by the
presence of the Philadelphia chromosome (Ph+) result-
ing from a translocation between chromosomes 9 and
22 [1]. Ph chromosome gives origin to the BCR-ABL1
fusion gene coding for a constitutive active tyrosine
kinase protein. Despite high response rate to specific
tyrosine kinase inhibitors (TKI), primary and secondary
resistance have been observed: upfront resistance is de-
fined as lack of initial response and acquired resistance
is defined as loss of an established response. BCR-ABL1* Correspondence: daniela.cilloni@unito.it
†Equal contributors
1Department of Clinical and Biological Sciences, University of Turin, Turin,
Italy
Full list of author information is available at the end of the article
© 2015 Rosso et al. This is an Open Access art
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/kinase domain (KD) mutations represent a well estab-
lished cause of resistance to tyrosine kinase inhibitors
[2]. Among different mutations identified the frequently
observed T315I is of particular concern since it is not ef-
fectively targeted by the majority of TKIs so far available
[3]. The only drug showing activity against T315I posi-
tive CML is ponatinib. [4]
Currently, the recommended method for BCR-ABL1
mutation detection is the sequencing of the KD [5]. This
is time consuming and it allows to reach a maximum
sensitivity of 10–15 %.
The latter point represents a limit, as frequently mu-
tated clones may be present at a lower percentage [6].
A relative new technique such the “ultra deep sequen-
cing” allows to reach a very high level of sensitivity buticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Experimental design: perfect PNA/DNA hybridization occurs when template sequence is w.t., thus leading to suppression of PCR
amplification. By contrast, when in presence of single base-pair mismatch (i.e. T315I, indicated by x), PNA/DNA duplex is strongly destabilized
allowing template amplification. Empty and filled arrows represent DNA primers used for PCR amplification and PNA competitor, respectively
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boratories [7].
The availability of a simple, sensitive and quick assay,
allowing a rapid detection of the T315I mutation is
therefore crucial, as the detection of this mutation repre-
sents an important element in clinical decision for CML
patients.
Peptide Nucleic Acid (PNA) is a potent DNA mimic
in terms of sequence specific hybridization. PNA/DNA
is thermally more stable than DNA/DNA or DNA/RNA
duplexes, [8] but PNA sequences cannot be extended
by DNA polymerase [9]. As consequence, PNA/DNA
duplex suppresses DNA amplification. Furthermore,
PNA/DNA hybridization shows a greater single-base-
pair mismatch discrimination than the corresponding
DNA/DNA duplex.
Based on this premise and previous data [10] we de-
veloped a novel and sensitive detection assay in order to
quickly and easily identify T315I mutation in CML pa-
tients by PNA directed PCR clamping. The experimentalFig. 2 Abl kinase domain T315I point mutation detection analysis by PNA
out on cDNAs isolated from patients affected by imatinib resistance CML is
(−) or in presence (+) of competitor PNA, at a concentration 3× greater than pr
internal positive control displaying the efficiency of template amplification. As re
mutation an efficient template amplification occurred. L: DNA ladder. Sensitivity
panel (b). Dilutions were as follow: 100, 20, 10, 5, 1, 0.5 and 0 % mutated (T315I)design forecasts that both PNA and PCR primer target
sites overlap, thus leading to a direct competition
towards complementary DNA (Fig. 1). When perfect
matching occurs PNA-template hybridization is favoured
more than primer template duplex and DNA amplifica-
tion is suppressed. Conversely, a single mismatch
destabilizes the PNA-template duplex, favouring the
hybridization between template and primer thus allowing
template amplification. Competitor PNA sequence was
designed to perfectly match wild-type (WT) template se-
quence. Therefore, when a single base pair mismatch oc-
curs (like in the case of T315I) PNA-template stability is
strongly impaired and DNA amplification favoured.
In addition, in order to identify the presence of BCR-
ABL1 T315I mutation at the single-cell level, we set up a
fluorescently-labelled PNA probe, coupled to FISH
technology.
This method allows to distinguish single mutated cells
from wild type cells in the context of Ph positive
hematopoiesis. Here we report the two strategies (PNAdirected PCR clamping. A representative result of the analysis carried
represented in panel (a). PCR amplification was carried-out in absence
imer FWD. The amplification performed without (−) PNA represents an
sult only when PNA-template duplex stability is weakened because of the
was assessed mixing, at different ratio, mutated (T315I) and w.t. template
versus w.t. template
Fig. 3 Detection of BCR-ABL T315I mutation by PNA. Detection of BCR-ABL T315I mutation by PNA (green signal) in CD34+ cells enriched from
CML patients carrying T315I mutation. Panel a and b show T315I positive cells from a patient with 60 % of mutated cells positive cells, panel c
and d show T315I positive cells from a patient with 45 % of mutated cells. Negative control (e, f) is represented by a CML patient without T315I
mutation. No specific PNA green signal can be detected in the absence of the mutation
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specific detection of BCR-ABL1 T315I, applied in the
clinical setting of BCR-ABL T315I monitoring.
Methods
PNA-PCR clamping for BCR-ABL1 T315I mutation
The study was approved by the local ethic committee of San
Luigi Hospital, Orbassano, Turin. After written informed
consent BM aspirates were obtained from 17 imatinib resist-
ant CML patient and 1 Ph +Acute Lymphoblastic Leukemia
(ALL), all displaying T315I mutation detected by SangerSequencing. In addition, as negative control, 25 CML pa-
tients without mutations and 15 healthy subjects were ex-
amined. Detection of BCR-ABL1 was performed by capillary
Sanger Sequencing method and analyzed by sequencing
with BigDye terminator v3.1 (Applied Biosystem, Foster
City, California CA) and capillary electrophoresis on ABI
PRISM 3130XL (Applied Biosystem, Foster City, California
CA). The sensitivity of this method was previously estimated
by serial dilutions experiments to be approximately10 %.
Primer Sequences were as follow:
FWD: 5’-tatcatcactgagttcatgacc-3’;
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PNA competitor: OO-atatcatcactgagttcat-Lys
Competitor PNA sequence was designed to perfectly
match WT template sequence.
PNA-PCR clamping conditions for BCR-ABL1 T315I
mutation detection were as follow:
1st step PCR: 94 °C 3 min, (94 °C 30 s, 55 °C 30 s, 72 °C
1 min 40 s) for 40 cycles, 72 °C 5 min; 2nd step PCR: 94 °C
3 min, (94 °C 30 s, 65 °C 20 s, 55 °C 50 s, 72 °C 15 s) for
30 cycles. Sensitivity was assessed mixing, at different ratio,
mutated (T315I) and WT template. Dilutions were as
follow: 100, 20, 10, 5, 1, 0.5 and 0 % T315I mutated versus
WT template. PCR amplification was carried-out in
absence (−) or in presence (+) of competitor PNA, at a
concentration 3× greater than primer FWD. The amplifi-
cation performed without (−) PNA represents an internal
positive control displaying the efficiency of template
amplification.
PNA FISH for the detection of BCR-ABL1 T315I mutation
In addition, for the detection of T315I mutation in pro-
genitor cells we set up a method based on fluorescently-
labelled PNA probe (PNA FISH). CD34+ cells were
enriched by magnetic cell sorting (MACS; Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s protocol. PNA probe was designed on
the human BCR-ABL1 T315I cDNA. The single nucleo-
tide mismatch falls just in the middle of the sequence. The
probe has been further tagged by fluorescinated dye at its
amino-terminus. The sequence is as follow: Alexa488-OO-
TATCATTGAGT-Lys. Detection of BCR-ABL T315 by
PNA FISH was performed as previously described [10]. At
least 500 cells have been evaluated for each sample. A posi-
tive control is added in each reaction to distinguish be-
tween negative results and lack of hybridization.
Results and discussion
PNA FISH and PNA direct PCR clamping allow to detect
T315I mutation in CML patients
Twelve patients displaying T315I mutations and 15 with
BCR-ABL1 WT were examined either by direct DNA se-
quencing or by PNA directed PCR clamping displaying
identical readout. The results and PCR conditions are
summarized in Fig. 2 panel a. As expected, when the af-
finity between PNA and template is lowered due to the
presence of the T315I mutation, DNA template is effi-
ciently amplified. By contrast, in case of WT template
the high affinity PNA/template duplex abolished PCR
amplification. To test the sensitivity of the method, serial
dilutions with WT and mutated T315I templates were
performed keeping constant the total template amount.
Surprisingly, the method displays a quite high sensitivity,
allowing to detect amount of mutated template as low as
0.5 % (Fig. 2, panel b), which are not identified byclassical sequencing allowing the identification of T315I
mutation even when present at low amount. This
method is highly sensitive, specific and cheap and could
be applied even in laboratory not equipped for more so-
phisticated analysis. Five out of 17 CML patients carry-
ing T315I, 1 Ph + ALL and 10 WT CML patients have
been tested by PNA FISH.
This technique allowed us to identify T315I mutation
at a single cell level. In particular we applied this tech-
nique to CD34+ cells to investigate the mutation in the
progenitor cell compartment.
More in details, we found a residual amount of 3 % of
CD34+ positive cells in a patient who became negative
for the T315I mutation by Sanger sequencing after pona-
tinib treatment and acquired T317 mutation at the time
of evaluation by PNA. In additional 4 patients positive
for T315I mutation by Sanger sequencing, PNA FISH
detected the mutation in respectively 20, 35, 45 % (Fig. 3
panel c, d) and 60 % (Fig. 3 panel a, b) of CD34+ cells.
Finally in the case of Ph + ALL with increasing values of
BCR-ABL1 transcript during dasatinib treatment and
negative for T315I by Sanger sequencing we found about
2 % of cells with T315I mutation by PNA FISH. These
cells were undetectable after hematopoietic stem cell
transplant, in accordance with a progressive decrease of
BCR-ABL1 transcript.Conclusions
We suggest that this approach could be extended to
other relevant and frequent BCR-ABL1 mutations thus
allowing to drive clinical decisions after TKI failure. Im-
portantly, it is now known that the emergence of com-
pound mutations in a BCR-ABL1 allele usually confer
ponatinib resistance. More in general, it was shown that
BCR-ABL1 compound mutants confer different levels of
TKI resistance [11], thus requiring a rational and patient
adapted selection of drugs to optimize the clinical out-
come. PNA-FISH allows to identify compound mutation
in single cells and to predict response to therapy. Fur-
thermore, PNA-FISH technology allows to provide an
answer to many questions including the possibility of
the persistence of mutated stem/progenitor cells in pa-
tients in MMR and the significance of the presence of
small mutated clones at diagnosis. Finally, it allows to
follow up clonal evolution during TKI therapy.
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